KDR and neoplasm: To better understand the combination potential of VEGFR-2 with PD-L1 therapy and determine if the increased intra-tumor T cell infiltration induced by anti-VEGFR-2 therapy is a primary mechanism improving the benefit of PD-L1 checkpoint blockade, we evaluated the combined therapy in MC38 and an additional syngeneic tumor model EMT-6.